DOP2021000031A - Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos - Google Patents
Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticosInfo
- Publication number
- DOP2021000031A DOP2021000031A DO2021000031A DO2021000031A DOP2021000031A DO P2021000031 A DOP2021000031 A DO P2021000031A DO 2021000031 A DO2021000031 A DO 2021000031A DO 2021000031 A DO2021000031 A DO 2021000031A DO P2021000031 A DOP2021000031 A DO P2021000031A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- heteroaryl
- therapeutic agents
- compounds substituted
- sulfonamide compounds
- tautomers
- Prior art date
Links
- -1 SULFONAMIDE COMPOUNDS Chemical group 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 150000008331 benzenesulfonamides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725956P | 2018-08-31 | 2018-08-31 | |
| PCT/US2019/048917 WO2020047323A1 (en) | 2018-08-31 | 2019-08-29 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000031A true DOP2021000031A (es) | 2021-03-31 |
Family
ID=67953876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000031A DOP2021000031A (es) | 2018-08-31 | 2021-02-19 | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10981905B2 (https=) |
| EP (1) | EP3844150A1 (https=) |
| JP (1) | JP7450606B2 (https=) |
| KR (1) | KR20210054510A (https=) |
| CN (1) | CN112638879B (https=) |
| AU (1) | AU2019331005B2 (https=) |
| BR (1) | BR112021000209A2 (https=) |
| CA (1) | CA3110853A1 (https=) |
| CL (1) | CL2021000443A1 (https=) |
| CO (1) | CO2021001433A2 (https=) |
| CR (1) | CR20210099A (https=) |
| DO (1) | DOP2021000031A (https=) |
| EA (1) | EA202190395A1 (https=) |
| EC (1) | ECSP21013035A (https=) |
| IL (1) | IL279810B2 (https=) |
| JO (1) | JOP20200337A1 (https=) |
| MA (1) | MA53489A (https=) |
| MX (1) | MX2021001380A (https=) |
| MY (1) | MY207670A (https=) |
| NI (1) | NI202100013A (https=) |
| PE (1) | PE20211066A1 (https=) |
| PH (1) | PH12021550381A1 (https=) |
| SG (1) | SG11202100109TA (https=) |
| TW (1) | TW202115018A (https=) |
| WO (1) | WO2020047323A1 (https=) |
| ZA (1) | ZA202100593B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
| KR20240030592A (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 아이엔테라퓨틱스 | 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법 |
| US20250034108A1 (en) * | 2023-07-07 | 2025-01-30 | Novartis Ag | Sodium channel blockers |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| EP0981327B1 (en) | 1997-05-07 | 2002-11-06 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
| US8202861B2 (en) | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP2008524244A (ja) | 2004-12-17 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | 水酸化ステロイド脱水素酵素阻害剤 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2624726A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| NZ593074A (en) | 2005-12-21 | 2012-04-27 | Vertex Pharma | sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels |
| EP2054385A2 (en) | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Phenyl, pyridine and quinoline derivatives |
| US7968556B2 (en) | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US7935779B2 (en) | 2008-03-07 | 2011-05-03 | Great Eastern Resins Industrial Co., Ltd. | Synthesis of polyimides (PI) from poly-carbodiimides and dianhydrides by sequential self-repetitive reaction (SSRR) |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| RU2011103451A (ru) | 2008-07-01 | 2012-08-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| EP2606051B1 (en) | 2010-08-20 | 2016-10-05 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| JP2014532660A (ja) | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| KR102038607B1 (ko) | 2012-10-15 | 2019-10-30 | 주식회사 대웅제약 | 소디움 채널 차단제, 이의 제조방법 및 이의 용도 |
| JP2015535252A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
| EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| UA120353C2 (uk) | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| AU2014370407B2 (en) | 2013-12-23 | 2018-03-29 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2016177340A1 (zh) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| US10519147B2 (en) | 2015-12-18 | 2019-12-31 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN114984003B (zh) | 2016-05-03 | 2024-08-27 | 拜耳制药股份公司 | 芳族磺酰胺衍生物 |
| PL3458449T3 (pl) | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| WO2018093694A1 (en) | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) * | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
-
2019
- 2019-08-29 KR KR1020217005599A patent/KR20210054510A/ko active Pending
- 2019-08-29 SG SG11202100109TA patent/SG11202100109TA/en unknown
- 2019-08-29 JP JP2021510434A patent/JP7450606B2/ja active Active
- 2019-08-29 IL IL279810A patent/IL279810B2/en unknown
- 2019-08-29 MY MYPI2021000075A patent/MY207670A/en unknown
- 2019-08-29 BR BR112021000209-0A patent/BR112021000209A2/pt unknown
- 2019-08-29 CR CR20210099A patent/CR20210099A/es unknown
- 2019-08-29 EA EA202190395A patent/EA202190395A1/ru unknown
- 2019-08-29 JO JOP/2020/0337A patent/JOP20200337A1/ar unknown
- 2019-08-29 MX MX2021001380A patent/MX2021001380A/es unknown
- 2019-08-29 US US16/556,055 patent/US10981905B2/en active Active
- 2019-08-29 WO PCT/US2019/048917 patent/WO2020047323A1/en not_active Ceased
- 2019-08-29 CA CA3110853A patent/CA3110853A1/en active Pending
- 2019-08-29 MA MA053489A patent/MA53489A/fr unknown
- 2019-08-29 EP EP19768963.1A patent/EP3844150A1/en active Pending
- 2019-08-29 AU AU2019331005A patent/AU2019331005B2/en not_active Ceased
- 2019-08-29 CN CN201980055649.4A patent/CN112638879B/zh active Active
- 2019-08-29 PE PE2021000164A patent/PE20211066A1/es unknown
-
2020
- 2020-02-07 TW TW109103817A patent/TW202115018A/zh unknown
-
2021
- 2021-01-27 ZA ZA2021/00593A patent/ZA202100593B/en unknown
- 2021-02-09 CO CONC2021/0001433A patent/CO2021001433A2/es unknown
- 2021-02-19 DO DO2021000031A patent/DOP2021000031A/es unknown
- 2021-02-22 CL CL2021000443A patent/CL2021000443A1/es unknown
- 2021-02-23 PH PH12021550381A patent/PH12021550381A1/en unknown
- 2021-02-24 US US17/183,401 patent/US11639351B2/en active Active
- 2021-02-25 EC ECSENADI202113035A patent/ECSP21013035A/es unknown
- 2021-02-25 NI NI202100013A patent/NI202100013A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21013035A (es) | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos | |
| ECSP20079861A (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| CO2018012485A2 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos | |
| MX2020004405A (es) | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| MX2019005243A (es) | Derivados de indazol como antagonistas de integrina alfa v. | |
| CO2017012545A2 (es) | Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ) | |
| ECSP19072975A (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco | |
| DOP2020000234A (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |